The earnings call reflects a highly positive sentiment with the successful launch and strong initial uptake of Vykat XR. The company's robust financial position and broad payer coverage further underscore the positive outlook. However, there are some uncertainties regarding future revenue streams and the upcoming challenges in the European market.

Company Guidance

During Soleno Therapeutics' second-quarter 2025 earnings call, the company highlighted several key metrics reflecting their commercial success. The launch of Vykat XR, the first FDA-approved treatment for hyperphagia in individuals with Prader-Willi Syndrome (PWS), generated $32.7 million in net revenue within the quarter. The company reported 646 patient start forms and 295 unique prescribers from launch through June 30. Approximately 33% of all insured lives in the United States are covered, equating to over 100 million lives. Soleno's financial results also showed a net loss of $4.7 million, with $293.8 million in cash and equivalents at the end of the quarter. The company is focused on expanding Vykat XR's reach in the EU, having submitted a marketing authorization application to the EMA.

Successful Launch of Vykat XR

The launch of Vykat XR for Prader-Willi Syndrome (PWS) has been well received, with strong initial demand and steady growth in patient starts and prescribers. Since the launch, 646 patient start forms have been received, and 295 unique prescribers have been identified.

Significant Revenue Generation

Soleno Therapeutics reported total net revenue of $32.7 million for the second quarter, reflecting strong demand for Vykat XR. This marks the first revenue generation for the drug following FDA approval in March.

Strong Financial Position

The company raised an additional $230 million through an offering, bringing the total pro forma cash balance to over $500 million, ensuring sufficient capital for U.S. launch and potential EU expansion.

Broad Payer Coverage Achieved

Vykat XR has achieved approximately 33% coverage among insured lives, covering over 100 million lives in the U.S. across commercial, Medicaid, and Medicare channels.

Positive Market Reception

The response from patients, physicians, and payers has been exceptionally encouraging, indicating strong market acceptance and recognition of the therapeutic need for Vykat XR.

Soleno Therapeutics (SLNO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SLNO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	0.05 / -	-1.83	―	―	―
Aug 06, 2025	2025 (Q2)	-0.45 / -0.09	-0.57	84.21% (+0.48)	―
May 07, 2025	2025 (Q1)	-0.97 / -0.95	-0.59	-61.02% (-0.36)	―
Feb 27, 2025	2024 (Q4)	-0.97 / -1.27	-0.33	-284.85% (-0.94)	―	―
Nov 06, 2024	2024 (Q3)	-0.60 / -1.83	-0.95	-92.63% (-0.88)	―	―
Aug 07, 2024	2024 (Q2)	-0.57 / -0.57	-0.81	29.63% (+0.24)	―	―
May 10, 2024	2024 (Q1)	-0.37 / -0.59	-0.88	32.95% (+0.29)	―	―
Mar 06, 2024	2023 (Q4)	-0.27 / -0.33	-0.58	43.10% (+0.25)	―	―
Nov 07, 2023	2023 (Q3)	-0.58 / -0.95	-0.76	-25.00% (-0.19)	―	―
Aug 08, 2023	2023 (Q2)	-0.83 / -0.81	-0.9	10.00% (+0.09)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SLNO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$81.19	$78.71	-3.05%
May 07, 2025	$74.66	$76.26	+2.14%
Feb 27, 2025	$44.99	$48.82	+8.51%
Nov 06, 2024	$56.86	$57.11	+0.44%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Soleno Therapeutics Inc (SLNO) report earnings?

Soleno Therapeutics Inc (SLNO) is schdueled to report earning on Nov 05, 2025, TBA (Confirmed).

What is Soleno Therapeutics Inc (SLNO) earnings time?

Soleno Therapeutics Inc (SLNO) earnings time is at Nov 05, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SLNO EPS forecast?

SLNO EPS forecast for the fiscal quarter 2025 (Q3) is 0.05.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing